Key facts
- ADPT - Adaptive Biotechnologies Corp has 22 insiders with reported activity on this page.
- Net insider value flow over the last year: -$68,095,855.
- Recent transaction rows are available for direct filing-level review.
Insider Transactions Reported by 22 Insiders of Adaptive Biotechnologies Corp
- Symbol
- ADPT on Nasdaq
- Location
- Seattle, WA
Change
- Buy value: ; sell value: $68,095,855.
- Net share flow: -4,463,024.
Research use
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsNet insider flow leans to selling over the last 12 months. Net value: -$68,095,855.
Buys
$0
Shares: 0
Insiders: 0
Sells
$68,095,855
Shares: 4,463,024
Insiders: 9
Net
-$68,095,855
Shares: -4,463,024
Insiders: -9
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 2,850,563 | $0 | $40,341,443 | -$40,341,443 |
| 3-6 | 0 | 870,820 | $0 | $15,440,379 | -$15,440,379 |
| 6-9 | 0 | 741,641 | $0 | $12,314,034 | -$12,314,034 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Adaptive Biotechnologies Corp executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Chad M. Robins | CEO and Chairman, Director | $33,122,068 | -$24,919,160 | -43% | Filing P/S | 06 Apr 2026 |
| Harlan S. Robins | Chief Scientific Officer | $22,454,061 | -$8,518,453 | -28% | Filing P/S | 08 Apr 2026 |
| Susan Bobulsky | Chief Commercial Officer, MRD | $5,633,796 | -$544,421 | -8.8% | Filing P/S | 11 Mar 2026 |
| Julie Rubinstein | President and COO | $5,376,122 | -$13,371,111 | -71% | Filing P/S | 27 Apr 2026 |
| Francis Lo | Chief People Officer | $4,120,990 | -$4,656,869 | -53% | Mixed | 08 Apr 2026 |
| Peter M. Neupert | Director | $3,811,395 | Mixed | 04 Mar 2026 | ||
| Sharon Benzeno | Chief Commercial Ofc Imm Med | $3,592,130 | -$11,187,469 | -76% | Filing P/S | 11 Mar 2026 |
| Kyle Piskel | Chief Financial Officer | $3,347,694 | -$3,581,680 | -52% | Filing P/S | 18 May 2026 |
| Tycho Peterson | Chief Financial Officer | $1,828,542 | Filing P/S | 04 Mar 2024 | ||
| Katey Einterz Owen | Director | $1,399,708 | Mixed | 04 Mar 2026 | ||
| Robert Hershberg | Director | $988,823 | -$367,488 | -27% | Mixed | 04 Mar 2026 |
| Nitin Sood | Chief Commercial Officer, MRD | $887,157 | Mixed | 07 Aug 2023 | ||
| R. Mark Adams | Chief Operating Officer | $724,241 | Mixed | 10 Apr 2023 | ||
| Stacy L. Taylor | SVP and General Counsel | $626,780 | Filing P/S | 22 Aug 2024 | ||
| Michael J. Pellini | Director | $553,339 | Mixed | 04 Mar 2025 | ||
| Michelle Renee Griffin | Director | $217,343 | -$949,204 | -81% | Filing P/S | 11 Mar 2026 |
| Henning Thorsen | SVP, Commercial Operations | $120,022 | Mixed | 17 May 2021 | ||
| Leslie Trigg | Director | $106,996 | Mixed | 06 Mar 2023 | ||
| Kevin T. Conroy | Director | $94,858 | Mixed | 06 Mar 2023 | ||
| Chad M. Cohen | Chief Financial Officer | $89,225 | Mixed | 22 Dec 2021 | ||
| Lance Baldo | Chief Medical Officer | $70,916 | Mixed | 08 Mar 2022 | ||
| Jyoti Palaniappan | SVP, Diagnostics, T-Detect | $37,823 | Mixed | 19 Jul 2021 |
Top shareholders of Adaptive Biotechnologies Corp (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| VIKING GLOBAL INVESTORS LP |
13D/G
13F
|
Company |
19%
|
29,993,708
|
$416,312,667 | $0 | 31 Mar 2026 | |
| BlackRock, Inc. |
13D/G
13F
|
Company |
7.9%
|
11,992,448
|
$194,757,356 | +$33,318,016 | 31 Dec 2025 | |
| Amova Asset Management Americas, Inc. |
13D/G
13F
|
Nikko Asset Management Americas, Inc. · Company |
4.6%
|
6,833,137
|
$53,981,782 | $0 | 31 Dec 2024 | |
| Sumitomo Mitsui Trust Group, Inc. |
13D/G
13F
|
Company |
4.6%
|
6,833,137
|
$53,981,782 | $0 | 31 Dec 2024 | |
| INTEGRATED CORE STRATEGIES (US) LLC |
13D/G
|
Millennium Management LLC |
4.3%
|
6,292,634
|
$49,711,809 | $0 | 31 Dec 2024 | |
| Rubric Capital Management LP |
13D/G
|
— |
4.1%
|
6,256,847
|
$72,889,139 | $0 | 30 Jun 2025 | |
| ARK Investment Management LLC |
13D/G
13F
|
Company |
2.9%
|
4,398,669
|
$40,863,635 | -$15,506,311 | 31 May 2025 | |
| Chad M. Robins |
3/4/5
|
CEO and Chairman, Director |
1.4%
|
2,180,518
|
$33,122,068 | -$24,919,160 | 06 Apr 2026 | |
| Harlan S. Robins |
3/4/5
|
Chief Scientific Officer |
0.95%
|
1,512,058
|
$22,454,061 | -$8,518,453 | 08 Apr 2026 | |
| Susan Bobulsky |
3/4/5
|
Chief Commercial Officer, MRD |
0.27%
|
427,775
|
$5,633,796 | -$544,421 | 11 Mar 2026 | |
| Peter M. Neupert |
3/4/5
|
Director |
0.15%
|
240,315
|
$3,811,395 | — | 04 Mar 2026 | |
| Michelle Renee Griffin |
3/4/5
|
Director |
0.01%
|
15,625
|
$217,343 | -$949,204 | 11 Mar 2026 | |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
|
Company |
3.8%
|
6,094,144
|
$84,586,719 | — | 31 Mar 2026 | |
| WESTFIELD CAPITAL MANAGEMENT CO LP |
13F
|
Company |
3.4%
|
5,436,718
|
$75,461,646 | — | 31 Mar 2026 | |
| VANGUARD PORTFOLIO MANAGEMENT LLC |
13F
|
Company |
2.8%
|
4,491,474
|
$62,341,659 | — | 31 Mar 2026 | |
| Invesco Ltd. |
13F
|
Company |
2.8%
|
4,450,066
|
$61,766,916 | — | 31 Mar 2026 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
2.4%
|
3,857,422
|
$53,541,017 | — | 31 Mar 2026 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.3%
|
3,636,054
|
$50,476,677 | — | 31 Mar 2026 | |
| LORD, ABBETT & CO. LLC |
13F
|
Company |
2.2%
|
3,536,103
|
$49,081,000 | — | 31 Mar 2026 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
2%
|
3,242,077
|
$45,000,029 | — | 31 Mar 2026 | |
| STATE STREET CORP |
13F
|
Company |
2%
|
3,227,245
|
$44,794,161 | — | 31 Mar 2026 | |
| AMERIPRISE FINANCIAL INC |
13F
|
Company |
1.9%
|
3,017,341
|
$41,880,713 | — | 31 Mar 2026 | |
| BNP Paribas Asset Management Holding S.A. |
13F
|
Company |
1.7%
|
2,688,081
|
$37,310,564 | — | 31 Mar 2026 | |
| FRED ALGER MANAGEMENT, LLC |
13F
|
Company |
1.3%
|
2,063,146
|
$28,636,466 | — | 31 Mar 2026 | |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP |
13F
|
Company |
1.3%
|
1,995,202
|
$27,693,404 | — | 31 Mar 2026 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
1.2%
|
1,965,610
|
$27,282,666 | — | 31 Mar 2026 | |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. |
13F
|
Company |
1.2%
|
1,881,183
|
$26,111,000 | — | 31 Mar 2026 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
1.1%
|
1,750,601
|
$24,298,342 | — | 31 Mar 2026 | |
| Aristotle Atlantic Partners, LLC |
13F
|
Company |
1.1%
|
1,714,346
|
$23,795,122 | — | 31 Mar 2026 | |
| PRINCIPAL FINANCIAL GROUP INC |
13F
|
Company |
1.1%
|
1,704,887
|
$23,663,831 | — | 31 Mar 2026 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
0.98%
|
1,566,213
|
$21,741,000 | — | 31 Mar 2026 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.87%
|
1,392,332
|
$19,325,568 | — | 31 Mar 2026 | |
| Divisadero Street Capital Management, LP |
13F
|
Company |
0.83%
|
1,318,661
|
$18,303,015 | — | 31 Mar 2026 | |
| Nuveen, LLC |
13F
|
Company |
0.82%
|
1,304,160
|
$18,101,741 | — | 31 Mar 2026 | |
| Capricorn Fund Managers Ltd |
13F
|
Company |
0.81%
|
1,291,773
|
$17,929,809 | — | 31 Mar 2026 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.77%
|
1,227,917
|
$17,043,488 | — | 31 Mar 2026 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.72%
|
1,145,682
|
$15,902,066 | — | 31 Mar 2026 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.68%
|
1,081,366
|
$15,009,360 | — | 31 Mar 2026 | |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ |
13F
|
Company |
0.67%
|
1,072,331
|
$14,883,954 | — | 31 Mar 2026 | |
| Aberdeen Group plc |
13F
|
Company |
0.67%
|
1,070,627
|
$14,860,303 | — | 31 Mar 2026 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
0.64%
|
1,021,808
|
$14,182,695 | — | 31 Mar 2026 | |
| Blue Water Life Science Advisors, LP |
13F
|
Company |
0.63%
|
1,010,145
|
$14,020,813 | — | 31 Mar 2026 | |
| MORGAN STANLEY |
13F
|
Company |
0.61%
|
967,120
|
$13,423,648 | — | 31 Mar 2026 | |
| KENNEDY CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.58%
|
931,522
|
$12,929,525 | — | 31 Mar 2026 | |
| T. Rowe Price Investment Management, Inc. |
13F
|
Company |
0.58%
|
919,278
|
$12,760,000 | — | 31 Mar 2026 | |
| VANGUARD FIDUCIARY TRUST CO |
13F
|
Company |
0.55%
|
870,959
|
$12,088,911 | — | 31 Mar 2026 | |
| OBERWEIS ASSET MANAGEMENT INC/ |
13F
|
Company |
0.51%
|
806,951
|
$11,200,480 | — | 31 Mar 2026 | |
| TUDOR INVESTMENT CORP ET AL |
13F
|
Company |
0.49%
|
786,281
|
$10,913,580 | — | 31 Mar 2026 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.49%
|
785,783
|
$10,906,668 | — | 31 Mar 2026 | |
| JENNISON ASSOCIATES LLC |
13F
|
Company |
0.47%
|
753,073
|
$10,452,654 | — | 31 Mar 2026 |
Recent Insider Transactions by Companies or Individuals for Adaptive Biotechnologies Corp
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Kyle Piskel | ADPT | Common Stock | Sale | -1.2% | $40,620 | $13.04 | -3,115 | 256,725 | 18 May 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Sale | -4.8% | $270,897 | $14.23 | -19,037 | 377,802 | 27 Apr 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Options Exercise | 3.85% | 14,707 | 396,839 | 27 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Stock Option (right to buy) | Options Exercise | -24.3% | -14,707 | 45,731 | 27 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Common Stock | Sale | -4.75% | $267,221 | $14.02 | -19,060 | 382,132 | 24 Apr 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Options Exercise | 3.81% | 14,722 | 401,192 | 24 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Stock Option (right to buy) | Options Exercise | -19.6% | -14,722 | 60,438 | 24 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Common Stock | Sale | -4.7% | $261,884 | $13.74 | -19,060 | 386,470 | 23 Apr 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Options Exercise | 3.77% | 14,722 | 405,530 | 23 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Stock Option (right to buy) | Options Exercise | -16.4% | -14,722 | 75,160 | 23 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Common Stock | Sale | -4.65% | $269,318 | $14.13 | -19,060 | 390,808 | 22 Apr 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Options Exercise | 3.73% | 14,722 | 409,868 | 22 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Stock Option (right to buy) | Options Exercise | -14.1% | -14,722 | 89,882 | 22 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Common Stock | Sale | -7.26% | $453,595 | $14.66 | -30,941 | 395,146 | 21 Apr 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Options Exercise | 6.66% | 26,603 | 426,087 | 21 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Stock Option (right to buy) | Options Exercise | -20.3% | -26,603 | 104,604 | 21 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Common Stock | Sale | -4.55% | $277,323 | $14.55 | -19,060 | 399,484 | 20 Apr 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Options Exercise | 3.65% | 14,722 | 418,544 | 20 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Stock Option (right to buy) | Options Exercise | -11% | -14,722 | 119,326 | 20 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Common Stock | Sale | -4.51% | $277,704 | $14.57 | -19,060 | 403,822 | 17 Apr 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Options Exercise | 3.61% | 14,722 | 422,882 | 17 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Stock Option (right to buy) | Options Exercise | -9.9% | -14,722 | 134,048 | 17 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Common Stock | Sale | -4.46% | $270,271 | $14.18 | -19,060 | 408,160 | 16 Apr 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Options Exercise | 3.57% | 14,722 | 427,220 | 16 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Stock Option (right to buy) | Options Exercise | -9% | -14,722 | 148,770 | 16 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Common Stock | Sale | -4.42% | $278,467 | $14.61 | -19,060 | 412,498 | 15 Apr 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Options Exercise | 3.53% | 14,722 | 431,558 | 15 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Stock Option (right to buy) | Options Exercise | -8.26% | -14,722 | 163,492 | 15 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Common Stock | Sale | -4.37% | $277,514 | $14.56 | -19,060 | 416,836 | 14 Apr 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Options Exercise | 3.5% | 14,722 | 435,896 | 14 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Stock Option (right to buy) | Options Exercise | -7.63% | -14,722 | 178,214 | 14 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Common Stock | Sale | -4.33% | $250,599 | $13.15 | -19,060 | 421,174 | 13 Apr 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Options Exercise | 3.46% | 14,722 | 440,234 | 13 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Stock Option (right to buy) | Options Exercise | -100% | -14,722 | 0 | 13 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Common Stock | Sale | -4.29% | $243,307 | $12.77 | -19,060 | 425,512 | 10 Apr 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Options Exercise | 3.42% | 14,722 | 444,572 | 10 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Stock Option (right to buy) | Options Exercise | -64.5% | -14,722 | 8,109 | 10 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Common Stock | Sale | -4.25% | $264,202 | $13.86 | -19,060 | 429,850 | 09 Apr 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Options Exercise | 3.39% | 14,722 | 448,910 | 09 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Stock Option (right to buy) | Options Exercise | -39.2% | -14,722 | 22,831 | 09 Apr 2026 | Direct | ||
| Francis Lo | ADPT | Common Stock | Sale | -7.68% | $340,039 | $15.07 | -22,564 | 271,154 | 08 Apr 2026 | Direct |
| Francis Lo | ADPT | Common Stock | Options Exercise | 0.8% | 2,344 | 293,718 | 08 Apr 2026 | Direct | ||
| Francis Lo | ADPT | Stock Option (right to buy) | Options Exercise | -2.59% | -2,344 | 88,297 | 08 Apr 2026 | Direct | ||
| Harlan S. Robins | ADPT | Common Stock | Sale | -0.66% | $148,500 | $14.85 | -10,000 | 1,512,058 | 08 Apr 2026 | Direct |
| Chad M. Robins | ADPT | Common Stock | Sale | -1.68% | $566,025 | $15.19 | -37,263 | 2,180,518 | 08 Apr 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Sale | -6.65% | $458,920 | $14.83 | -30,941 | 434,188 | 08 Apr 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Options Exercise | 6.07% | 26,603 | 465,129 | 08 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Stock Option (right to buy) | Options Exercise | -41.5% | -26,603 | 37,553 | 08 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Common Stock | Sale | -4.17% | $258,454 | $13.56 | -19,060 | 438,526 | 07 Apr 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Options Exercise | 3.32% | 14,722 | 457,586 | 07 Apr 2026 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.